Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
News for ASAHI KAISEI CRP UNSP/ADR (AHKSY) reflects the breadth of Asahi Kasei Corporation’s activities across its Healthcare, Homes, and Material sectors. Company announcements highlight how this diversified manufacturer is reshaping its portfolio, advancing medical technologies, and developing new materials and electronic components.
In Healthcare, recent news features ZOLL Medical, an Asahi Kasei company, and its LifeVest wearable cardioverter defibrillator. Updates describe launches of next-generation LifeVest systems and garments, along with references to clinical evidence and AI-enhanced algorithms designed to reduce false alarms. Asahi Kasei Pharma also appears in news items, including the planned relocation of its global R&D hub to Shonan Health Innovation Park to strengthen drug discovery and open innovation.
Within the Material sector, news coverage includes Asahi Kasei Microdevices (AKM) and its sensing technologies, such as millimeter-wave radar solutions for real-time swallowing detection, gesture recognition based on electromyography, and AgeTech and PetTech applications like fall detection, smart diapers, cage monitoring systems, and smart pet collars. Other articles highlight advanced materials, including PIMEL™ photosensitive dielectric recognized by a TSMC Excellent Performance Award, and battery-related innovations such as high ionic conductive electrolyte technology licensed to EAS Batteries.
Investors and followers of AHKSY can use this news stream to track Asahi Kasei’s portfolio transformation under its "Trailblaze Together" plan, including structural reforms like the divestiture of the Daramic lead battery separator business, the planned phase-out of hexamethylene diamine production, and the integration of Asahi Kasei Advance with Teijin Frontier. Bookmark this page to monitor ongoing developments in pharmaceuticals, critical care, electronics, advanced materials, and sustainability-related initiatives that Asahi Kasei highlights in its public communications.
Asahi Kasei Pharma (OTC: AHKSY) will relocate its global R&D hub from Ohito, Shizuoka to Shonan Health Innovation Park (Shonan iPark) in January 2027.
The move aims to strengthen global R&D for pharmaceuticals, accelerate open innovation with external partners, access a life-science ecosystem including AI/digital health and academia, and attract R&D talent via shared labs and state-of-the-art equipment. The company intends to focus on priority disease areas (autoimmune, severe infectious, transplantation, renal) and align relocation with its medium-term plan prioritizing pharmaceuticals and ongoing M&A.
Asahi Kasei Microdevices (AHKSY) and Aizip partnered to demo AI-enhanced sensing for health and wearables at CES 2026. AKM supplies millimeter-wave radar for real-time, non-wearable swallowing detection and an AK05611-based wristband for EMG gesture recognition; Aizip provides lightweight on-device AI that converts radar and EMG signals into clinical-grade insights locally and in real time. The swallowing demo targets aspiration-risk detection in older adults without cloud latency; the gesture demo maps forearm EMG to commands like open/close/tap. Both solutions emphasize privacy, low power, and immediate alerts to caregivers.
Asahi Kasei (OTC:AHKSY) received a 2025 TSMC Excellent Performance Award for “Excellent Technology Development and Production Support” in Advanced Packaging materials at TSMC’s Supply Chain Management Forum on November 25, 2025. The award recognizes suppliers for innovation and production support in advanced packaging over the past year.
Asahi Kasei highlighted its PIMEL™ photosensitive dielectric as a key product, noted the designation of the electronics business as a first priority in its Trailblaze Together medium-term plan (fiscal 2025–2027), and announced investments to ensure stable supply, including the launch of a new plant to support advanced semiconductor and AI-related applications.
Asahi Kasei (OTC:AHKSY) will discontinue production of hexamethylene diamine (HMD) as part of a structural reform to improve capital efficiency and strengthen earnings. The company said the HMD phase-out will be completed by April 2027 and will not affect its PA66 resin and filament production in Nobeoka or HDI production in Hyuga, both in Miyazaki Prefecture. Affected employees will be reassigned internally. The company expects the impact on consolidated performance forecasts to be immaterial. Under its three-year medium-term plan "Trailblaze Together," Asahi Kasei is reallocating resources to four growth pillars: pharmaceuticals, critical care, overseas homes, and electronics. Recent moves cited include the divestiture of Daramic and expanded Pimel capacity.
Asahi Kasei (OTC:AHKSY) completed the divestiture of Daramic, its lead battery separator business, to Kingswood Capital Management, LP, with the transfer closing on December 1, 2025. The company said the sale’s effect on consolidated fiscal 2025 results is immaterial.
Asahi Kasei will reallocate resources toward high‑growth pillars under its three‑year plan "Trailblaze Together", prioritizing pharmaceuticals, critical care, overseas homes, and electronics, and expanding lithium‑ion battery separator investments (Hipore wet‑process) in North America, Japan, and Korea.
Asahi Kasei (AHKSY) and Teijin agreed to merge Asahi Kasei Advance into Teijin Frontier by absorption, effective October 1, 2026, creating a joint venture with Teijin 80% and Asahi Kasei 20%. The integration will transfer Hangzhou Asahikasei Textiles to Asahi Kasei Advance prior to the merger and aims to combine sales networks, procurement and manufacturing platforms to drive sustainable growth and corporate value.
The release states the effect on Asahi Kasei consolidated earnings is immaterial and leaves surviving-company details (name, capital, assets) as TBD.
Asahi Kasei (OTC:AHKSY) won the 2025 BioTech Breakthrough Award for Biomanufacturing Innovation of the Year for its Planova™ FG1 virus removal filter.
FG1 uses a new hydrophilic modified polyethersulfone membrane to combine high permeability and robust virus retention, reporting a water flux of 1,220 L/m²·hr at 49.7 psi, maintaining virus clearance after a 120‑minute process pause, and supporting steam‑in‑place and clean‑in‑place integration. The release notes ongoing investment in Planova, including a May 2024 assembly plant start in Nobeoka City, Miyazaki, and a Planova workshop on Nov 13–14, 2025 in Monaco.
Asahi Kasei Microdevices (AHKSY) will showcase AgeTech and PetTech sensing solutions at CES® 2026 on November 12, 2025, in the Digital Health section at the Venetian Expo, booth 54829.
Key demos include the AK5816AIM millimeter-wave radar for privacy-preserving fall detection (recognizes falls within 10 seconds) and a next-generation energy-harvesting smart diaper that uses urine as an electrolyte to power a Bluetooth Low Energy transmitter and estimate urination frequency and volume without batteries.
PetTech reveals include a cage monitoring system that tracks breathing and heart rate for dogs and cats and a smart pet collar measuring body-surface and ambient temperature with Bluetooth alerts for fever or heat.
Asahi Kasei (AHKSY) licensed its acetonitrile-containing, high ionic conductivity electrolyte to German battery maker EAS Batteries for use in a new ultra-high-power LFP cylindrical cell, UHP601300 LFP 22. The cell has 22 Ah capacity, delivers 2,550 W/kg continuous (40C, 880 A) — ~60% above conventional electrolytes — and 3,760 W/kg on a 2-second pulse (10% improvement). Cycle life reached 2,400 cycles at 5C/5C (100% DoD) to 80% capacity; a fast full charge/discharge was demonstrated in 24 minutes (110 A). The product is scheduled for market launch by March 2026. Asahi Kasei and EAS plan sublicensing to global OEMs and aim to expand commercialization under Asahi Kasei’s MTP licensing targets.
Asahi Kasei (AHKSY) announced that Nefecon (TARPEYO) is included in the KDIGO 2025 Clinical Practice Guideline for IgA nephropathy (IgAN) and IgA vasculitis. KDIGO recommends a 9-month course of Nefecon for patients at risk of progressive kidney-function loss, citing phase 3 NefIgArd randomized placebo-controlled trial results showing reduced loss of kidney function and reduced proteinuria in adults on stable RAS inhibitor therapy. KDIGO also notes Nefecon is the only approved IgAN therapy shown to reduce pathogenic IgA levels. Adverse events in the trial were described as mild or moderate and generally resolved after treatment stopped.